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Design: Observational in vitro study.
Setting: Single-center university hospital.
Participants: In vitro CPB systems used for pediatric cardiac surgery.
Interventions: Three full neonatal, infant, and pediatric CPB systems were primed according to hospital protocol and kept running for 6 hours.
Midazolam, propofol, sufentanil, and methylprednisolone were added to the venous side of the systems in doses commonly used for induction of
general anesthesia. Blood samples were taken from the postoxygenator side of the circuit immediately after injection of the drugs and after 2, 5,
7, 10, 30, 60, 180, and 300 minutes.
Measurements and Main Results: Linear mixed model analyses were performed to assess the relationship between log-transformed drug concen-
tration (dependent variable) and type of CPB system and sample time point (independent variables). The mean percentage of drug recovery after
60 and 180 minutes compared with T1 was 41.7% (95% confidence interval [CI] 35.9-47.4) and 23.0% (95% CI 9.2-36.8) for sufentanil, 87.3%
(95% CI 64.9-109.7) and 82.0% (95% CI 64.6-99.4) for midazolam, 41.3% (95% CI 15.5-67.2) and 25.0% (95% CI 4.7-45.3) for propofol, and
119.3% (95% CI 101.89-136.78) and 162.0% (95% CI 114.09-209.91) for methylprednisolone, respectively.
Conclusions: The present in vitro experiment with neonatal, infant, and pediatric CPB systems shows a variable recovery of routinely used drugs
with significant differences between drugs, but not between system categories (with the exception of propofol). The decreased recovery of
mainly sufentanil and propofol could lead to suboptimal dosing of patients during cardiac surgery with CPB.
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2 A. van Saet et al. / Journal of Cardiothoracic and Vascular Anesthesia 00 (2019) 19CARDIOPULMONARY BYPASS (CPB) is necessary to to-three eighths connection piece. A venous reservoir completedfacilitate most cardiac surgery in children. The effect of CPB
on in vivo drug concentrations in patients can be profound and
is attributed to hemodilution, altered hemodynamic status,
hypothermia, systemic inflammation, changes in acid-base sta-
tus, exclusion of the lungs from the circulation, and hemofiltra-
tion.1 Furthermore, the plastic components of the CPB system
themselves have been shown to absorb drugs.2-7
In the authors’ institution, multiple experiments have been
performed to determine in vitro drug recovery in extracorpo-
real membrane oxygenation (ECMO) systems.8,9 Drug recov-
ery has been defined as the concentration of drug present in
the priming fluid after a certain amount of time has passed
since addition of the drug to the CPB system.8,9 Previous pub-
lications have used the term absorption to indicate the decrease
in concentration of drug in the priming fluid. In the authors’
institution, recovery has been deemed a more precise definition
because not all drug is actually absorbed by the system compo-
nents. Drugs also are subject to spontaneous degradation, for
example, providing an altogether different reason for a
decrease in drug concentration than absorption of drug to com-
ponents of the CPB system.8 There is a lack of data in the liter-
ature concerning pediatric CPB systems. As part of the
authors’ CPB PHARM study, which aims to measure and
model drug concentrations during CPB for pediatric cardiac
surgery (registered at the Netherlands Trial Register
[NTR3579]), the in vitro experiments described herein were
undertaken. The ultimate goal is to incorporate these data into
in vivo population pharmacologic models.
Methods
The present study was conducted at the Department of Cardio-
thoracic Surgery of a tertiary teaching hospital. No human partic-
ipants were involved in the study, so the need for medical ethical
review board approval was waived according to Dutch law.
Soon to be expired CPB systems were made available free
of charge by Terumo Europe NV, Leuven, Belgium, and Sorin
Group, Mirandola, Italy. This research did not receive any spe-
cific grant from funding agencies in the public, commercial, or
not-for-profit sectors. There was no role for Terumo Europe
NV or Sorin Group in the design of the study, collection, anal-
ysis, and interpretation of data; writing of the report; or the
decision to submit the report for publication.
CPB Systems
Table 1 shows the composition of the different CPB systems
used. All systems contained a hollow-fiber membrane oxygena-
tor with a polymethylpentene membrane. For the neonatal and
pediatric systems an arterial filter was integrated in the oxygena-
tor, and for the infant system a stand-alone arterial filter was
used. Silicone and polyvinylchloride (PVC) tubing with differ-
ent lengths and diameters were used in the neonatal and infant
roller-pump systems. In the pediatric system a centrifugal pump
was used, and the silicone tubing was discarded. Tubing was
made continuous via a one fourth-to-one fourth or a one fourth-the systems. Terumo components of the systems were coated
with X-coating (poly[2-methoxyethylacrylate]), which is a non-
heparin biocompatible polymer with hydrophilic and hydropho-
bic properties. Sorin components of the systems were coated
with P.h.i.s.i.o. (Sorin) coating, which is a nonheparin, biomi-
metic layer consisting of a phosphorylcholine polymer.
All systems were placed on a conventional mast-mounted,
remote pump head console (St€ocker S5 Perfusion System;
Sorin Group) with a specific pediatric configuration.
Three full systems were assembled for each category (neo-
natal, infant, and pediatric) and primed according to hospital-
based protocol (Table 2). Priming fluid contained fresh frozen
plasma and Gelofusine (B. Braun, Melsungen, Germany). Red
blood cells were added to the priming to achieve a hematocrit
of 28%. Recently expired red blood cells and fresh frozen
plasma obtained from the authors’ local blood bank were used
for priming. The priming fluid was completed with human
albumin (Sanquin Plasma Products BV, Amsterdam, The
Netherlands) and 2 to 5 mL sodium bicarbonate 8.4% (Frese-
nius Kabi Nederland BV, Zeist, The Netherlands). Heparin
was added to the system according to hospital protocol to pre-
vent clotting.
The CPB systems were kept running for 6 hours. This is
the maximum runtime with guaranteed quality by the man-
ufacturers. The temperature was maintained at 36˚C.,
pCO2, and pH were measured with an iStat handheld
device (Abbot BV, Hoofddorp, The Netherlands) and main-
tained within physiological ranges by titration of sweep
gas flow, gas composition, and addition of sodium bicar-
bonate 8.4% if needed.
A flow rate of 0.5 L/min was maintained for the neonatal
circuits, 1.5 L/min for the infant circuits, and 3 L/min for the
pediatric circuits. Postmembrane pressures were kept at 100
mmHg by adapting the resistance using the venous clamp.
Drug Administration
For the neonatal system a standardized body weight of 5 kg
was used for drug amount calculations, 15 kg for the infant
system, and 30 kg for the pediatric system were used. Drugs
were added to the venous reservoir via a manifold sample port
in a dose that normally would be used for the induction of gen-
eral anesthesia according to the following authors’ institution’s
guidelines: midazolam (1 mg/mL; Actavis Group PTC ehf,
Hafnarfj€ordur, Iceland) 0.2 mg/kg; propofol (10 mg/mL; Fre-
senius Kabi Nederland BV) 2 mg/kg; sufentanil (50 mg/mL;
Hameln Pharma Plus GmbH, Hameln, Germany) 2 mg/kg; and
methylprednisolone (100 mg/mL; Pfizer BV, Capelle a/d IJs-
sel, The Netherlands) 30 mg/kg. Drugs were injected in the
same order for all systems. Between administration of each
drug and after administration of the last drug, the sample port
was flushed with 2 mL of 0.9% saline solution to prevent crys-
tallization or pooling of drug. Midazolam, propofol, sufentanil,
and methylprednisolone were used because these drugs are
commonly used for pediatric cardiac anesthesia in the authors’
institution.
Table 1
CPB Systems
Oxygenator Reservoir Arterial filter Venous Filter
Cardiotomy
Defoaming
Sponge
Silicone Tubing PVC Tubing Priming
Volume
Neonatal roller Capiox FX05 (Terumo
Europe NV, Leuven,
Belgium)
Hollow fiber
Polycarbonate housing,
polypropylene
membrane 0.5 m2
Priming volume 43 mL
X-coating
Open, hard shell
polycarbonate
Minimum capacity
15 mL
Maximum capacity
1,000 mL
Integrated polyester
screen type
Surface area 130 cm2
Pore size 32mm
Polyester screen
type
Pore size 47mm
Polyurethane Sorin Kids neonate set,
custom made, (Sorin
Group, Mirandola,
Italy)
Diameter 1=4 inch, length
1.10 m, 0.02 m2
contact surface area,
P.h.i.s.i.o. coating
Sorin Kids neonate set,
custom made (Sorin)
Diameter 1=4 inch, length
2.95 m, 0.069 m2 contact
surface area,
P.h.i.s.i.o. coating
230 mL
Infant roller Sorin Kids D101 (Sorin)
Hollow fiber
Polycarbonate housing,
polypropylene
membrane 0.61 m2
Priming volume 87 mL
P.h.i.s.i.o. coating
Open hardshell,
polycarbonate
Minimum capacity
30 mL
Maximum capacity
1,500 mL
Sorin Kids D131
stand-alone arterial
filter
Polycarbonate housing,
phosphoryl-chloride
screen type membrane
Surface area 27 cm2
Pore size 40mm
Priming volume 28 mL
Polyester
Pore size 51mm
Polyurethane Sorin Kids, custom made
Diameter 1=4 inch, length
1.05 m, 0.02 m2 contact
surface area
P.h.i.s.i.o. coating
Sorin Kids neonate set,
custom made
Arterial part diameter 1=4
inch, length 1.88 m
Venous part diameter 3/8
inch, length 1.51 m
Total 0.08 m2 contact
surface area
P.h.i.s.i.o. coating
420 mL
Pediatric
centrifugal
Revolution
(Sorin)
Pump casing
polycarbonate
Priming volume
57 mL
Capiox FX15 (Terumo
Europe)
Hollow fiber
Polycarbonate housing,
polypropylene
membrane 1.5 m2
Priming volume
144 mL
X-coating
Open hardshell
polycarbonate
Minimum capacity
70 or 200 mL
Maximum capacity
3,000 or 4,000 mL
Integrated polyester
screen type
Surface area 360 cm2
Pore size 32mm
Polyester screen
type
Pore size 47mm
Polyurethane None Sorin Kids Pediatric set,
custom made
Diameter 3/8 inch, length
4.87 m, 0.15 m2 contact
surface area
P.h.i.s.i.o. coating
700 mL
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Table 2
Priming Fluid Composition
Neonatal Infant Pediatric
Priming volume (mL) 263 430 683
RBC (mL) 135 235 365
FFP (mL) 30 40 50
Gelofusine (mL) 30 40 50
Albumin 20% (mL) 40 50 100
Mannitol 15% (mL) 20 50 100
NAHCO3 8.4% (mL) 8 15 18
Heparin (mL) 0.4 0.5 1
Flow (L/min) 0.5 1.5 3.5
Temperature (˚C) 36 36 36
Line pressure (mmHg) 100 100 100
Abbreviations: FFP, fresh frozen plasma; NAHCO3, Sodium bicarbonate;
RBC, red blood cells.
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Four-milliliter blood samples were taken from the arterial
(post oxygenator) side of the circuit via a manifold sample
port in a polypropylene (PLP) ethylenediaminetetraacetate
tube (7.2 mg) (BD Vacutainer, BD Life Sciences, Plymouth,
UK). Samples were taken immediately after injection of the
drugs (T1) and after 2, 5, 7, 10, 30, 60, 180, and 300 minutes.
Samples were stored at 4˚C until processing. After centrifu-
gation (10 min at 3,600 rpm), the supernatant serum was trans-
ferred to PLP cryogenic vials with PLP screw caps (Sarstedt
Aktiengesellschaft & Co, N€umbrecht, Germany) and stored at
80˚C until analysis.
Assay Methods
Drug concentrations for sufentanil, midazolam, propofol,
and methylprednisolone were measured using liquid chroma-
tography mass spectrometry. Methods were validated accord-
ing to US Food and Drug Administration guidelines for
bioanalytical method validation.10 All analyses included qual-
ity control samples, as is required for Food and Drug Adminis-
tration analyses, and were performed in International
Organization for Standardization- and Good Clinical Practice-
certified laboratories by a certified research technician.
Drug concentrations for sufentanil were measured using a
Thermo TSQ Vantage triple-stage quadrupole mass spectrome-
ter (Thermo Fisher Scientific, Waltham, MA) at the pharmacy
laboratory of the Erasmus Medical Center. Drug concentrations
for midazolam were measured using a Quattro Premier mass
spectrometer (Waters Corp, Milford, MA) at the pharmacy labo-
ratory of the Erasmus Medical Center. Propofol was measured
using a Thermo TSQ Quantiva triple-stage quadrupole mass
spectrometer (Thermo Fisher Scientific) at the pharmacy labora-
tory of the University Medical Center in Groningen, the Nether-
lands. Drug concentrations for methylprednisolone were
measured using a SCIEX Triplequad 6500+ mass spectrometer
(AB SCIEX, Concord, Ontario, Canada) and Analyst software,
Version 1.7 (AB SCIEX) at the Institute for Biomedical and
Pharmaceutical Research in N€urnberg-Heroldsberg, Germany.The lower limit of quantification was 0.25 mg/L for sufenta-
nil, 2.0 mg/L for midazolam, 100.0 mg/L for propofol, and 10
mg/L for methylprednisolone. The upper limit of quantifica-
tion (ULOQ) was 50.0 mg/L for sufentanil, 2,400 mg/L for
midazolam, unknown for propofol, and 30100 mg/L for meth-
ylprednisolone.
Statistical Analysis
The relationship between log-transformed drug concentra-
tion (dependent variable) and type of CPB system and sample
time point (independent variables) was assessed with linear
mixed model analyses. Linear mixed model analyses were
used because a correlation can be expected between repeated
measurements of the same variable (ie, drug concentration) in
the same subject (ie, individual CPB systems). Both indepen-
dent variables were treated as categorical variables, and a
2-way interaction effect between the type of CPB system and
sample time point was included in the model. To correct for
within-system correlations between time points, a random
intercept was used and we assumed a first-order autoregressive
error covariance matrix. This model specification was chosen
by comparing values of the Akaike information criterion
between different structures for the random effects and the
error covariance matrix.
For each time point and each CPB system, the difference
between the predicted log-transformed estimated marginal
means11 at T1 and the predicted log-transformed concentration
at the different time points was calculated, as was the 95% con-
fidence interval (CI) of this difference. Finally, this difference
and the 95% CI were exponentiated to obtain the percentage
drug recovery (the percentage of drug still present in the prim-
ing fluid) for T2 to T300. The maximum expected concentration
in case of perfect mixture of drug (MEC) was calculated by
dividing the amount of drug added to the CPB systems by the
total priming volume used because it was unclear whether mix-
ing of drug with the priming fluid would be complete at T1.
Spearman correlations were calculated to assess the rela-
tionship between drug recovery at 60 and 180 minutes and log
P, protein binding, and pKa among the 4 drugs (ie, with a sam-
ple size of n = 4 drugs). For each drug, the recovery used for
the calculation of this correlation was based on the estimated
marginal means of the linear mixed model.
Statistical analyses were performed using SPSS Statistics
for Windows, Version 24 (IBM Corp, Armonk, NY). All statis-
tical tests used a 2-sided significance level of 0.05.
Results
No technical problems were encountered during the experi-
ments. A total of 81 samples (27 for each CPB system cate-
gory) were analyzed. No loss of drug samples occurred.
Fig 1 shows predicted drug recovery (based on the estimated
marginal means of the linear mixed models) versus time for
propofol for each CPB system category. There was a sharp and
significant decline in recovery of propofol compared with T1
in all the system categories in the first 60 minutes, to 41.3%
Fig 1. Drug recovery versus time based on estimated marginal means for pro-
pofol, for each cardiopulmonary bypass system category, expressed as means
and 95% confidence interval based on the linear mixed models.
MEC, maximum expected concentration in case of perfect mixture of drug.
*p < 0.002.
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added drug was lost from the circulating prime fluid at that
time. After that, recovery continued to decrease slightly but
significantly throughout the study period to 25% (95% CI 4.7-
45.3) after 180 minutes and 19% (95% CI 5.2-32.8) after 300
minutes. Based on the interaction effects in the mixed models,
there was a significant difference in the pattern of recovery
over time among systems for propofol (p < 0.001). Recovery
was the greatest in the infant system, followed by the pediatric
system. The neonatal systems appear to absorb the largest
amount of propofol to their system components.
Fig 2 shows predicted drug recovery (based on the estimated
marginal means of the linear mixed models) versus time for
sufentanil, midazolam, and methylprednisolone. Because there
was no significant interaction effect between the type of CPB
system and sample time point for sufentanil (p = 0.111), mida-
zolam (p = 0.213), or methylprednisolone (p = 0.829), a single
graph was used to depict decrease of drug recovery over time
for all 3 systems. The pattern of decline in recovery of sufenta-
nil shows stable drug concentrations in the first 7 minutes,
with a significant decline compared with T1 from T10 onward.
Drug recovery was 41.7% (95% CI 35.9-47.4) at
60 minutes. After 60 minutes, recovery continued to decrease
slightly but significantly throughout the study period. For
sufentanil, recovery was 23.0% (95% CI 9.2-36.8) after
180 minutes and 15% (95% CI 1.3-31.3) after 300 minutes.
For midazolam, there also was stable drug recovery in the
first 7 minutes. The decline in drug recovery compared with
T1 reached significance at T10 and from T60 forward. Drug
recovery was 87.3% (95% CI 64.9-109.7) after 60 minutes and
82.0% (95% CI 64.6-99.4) after 180 minutes. For methylpred-
nisolone, there was stable recovery of drug in the first30 minutes. After that, recovery increased significantly com-
pared with T1 to values much higher than 100%.
No significant correlation between log P and percentage
recovery of the 4 drugs at 180 minutes (r 0.324; p = 0.304)
was found. In addition, a decreased recovery of highly protein-
bound drugs (r =0.822; p = 0.007) was found. The third fac-
tor that correlated to percentage recovery at 180 minutes in
the present study was pKa (r = 0.822; p = 0.007).
Discussion
These in vitro experiments investigated drug recovery in 3
different pediatric CPB systems used in the authors’ center.
Decrease of drug concentration in the circulating prime fluid
for propofol and sufentanil was fast in the first 60 minutes.
Because 60 minutes is a relatively common bypass time in
pediatric cardiac surgery, this period is clinically very relevant.
The decreasing speed of reduction in drug concentration after
60 minutes may be an indication of near complete saturation
of binding places on the different components of the CPB sys-
tems. It is, however, unknown whether there is a finite amount
of binding places and if complete saturation of these binding
places is possible. Hammaren et al.12 and Myers et al.13 have
shown that for propofol there appears to be no maximum satu-
ration of binding places in complete adult CPB systems, even
at very high propofol concentrations. Binding of propofol may
be concentration dependent.12 In contrast, complete saturation
of oxygenator membrane fragments has been shown for fenta-
nyl in in vitro studies.5
In the present study, midazolam recovery was remarkably
large in both centrifugal and roller-pump systems. Unfortu-
nately, there are no in vitro studies of pediatric CPB systems
with which to compare the present study’s results. An ECMO
study performed in the authors’ hospital showed a recovery
pattern similar to the present experiment in systems with a cen-
trifugal pump.8 In roller-pump systems there was just 7.5%
recovery after 2 minutes and 0.6% recovery after 180 minutes.
For midazolam, however, it must be taken into account that
the concentrations measured in the present study were far
above the ULOQ. The authors believe that this may at least
partly be the reason that the MEC was lower than the measured
concentrations. This introduced an unknown amount of bias,
but the authors do not expect that this measurement bias would
explain the high recovery rates. An error in the addition of
medication to the system or a laboratory error also were not
expected because the experiments were performed on different
days for the different systems and all the percentage recovery
versus time curves show a similar pattern.
Methylprednisolone concentrations in the first hour were
much lower than would be anticipated from the MEC. This
most likely was caused by a problem with the mixing of meth-
ylprednisolone added to the system with the priming fluid.
Another explanation would be very fast binding of methyl-
prednisolone to components of the CPB system and release of
drug from those binding sites after 60 minutes. However, it is
unknown whether binding of drug to components of a CPB
system is a reversible process.
Fig 2. Drug recovery versus time based on estimated marginal means for midazolam, sufentanil, and methylprednisolone, expressed as means and 95% confidence
interval based on the linear mixed models.
MEC, maximum expected concentration in case of perfect mixture of drug.
*p < 0.05
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suggest that drug characteristics influence the interaction with
components of the CPB system (Table 3). From previous studies
in ECMO systems, recovery of drugs seems to be highly depen-
dent on lipophilicity.8,9,14,15 In the present study, no correlation
between log P and recovery percentage was found. This likely
was caused by the recovery profile of midazolam. Significantly
decreased recovery of highly protein-bound (>80%) drugs also
was shown in a previous publication.15 We found a generally
decreased recovery of highly protein-bound drugs, which may
be caused by binding of drug to protein adhered to system com-
ponents.15 The similar recovery patterns of propofol and sufen-
tanil suggest that there is a common physicochemical propertyof both drugs causing this effect. The authors, however, cannot
explain why the recovery pattern of midazolam is different in
our study because the physicochemical properties known to
influence recovery are very similar to those of propofol and
sufentanil. Another factor correlated to the percentage recovery
at 180 minutes in the present study was pKa. To the authors’
knowledge no correlation between pKa and recovery has been
described previously. The surface-coated CPB systems are neg-
atively charged, making electrostatic attraction of positively
charged molecules a possible mechanism for absorption of
drugs to CPB system components. Drugs with a high pKa are
unlikely to be dissociated at normal pH, however, which was
maintained during the study period.
Table 3
Drug Physicochemical Data19
Blood/Plasma Ratio Log P Protein Binding (%) Vd (L/kg) pKa
Methylprednisolone Unavailable 2.06 78 Unavailable 12.58
Sufentanil 0.75 3.4 Unavailable Unavailable 8.86
Propofol Unavailable 3.81 95-99 Unavailable for children 10.98
Midazolam 0.75 3.89 97 Children 6 mo-16 y 1.24-2.02 10.98
Abbreviations: Vd, volume of distribution.
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ent types of CPB system was found only for propofol. In gen-
eral, one would expect a larger system to have more binding
sites for drugs and thus a lower recovery for drugs with similar
properties. The surface area of the oxygenator and the PVC
tubing in the authors’ pediatric systems are much larger than
those in their neonatal and infant systems. In the present study,
midazolam and methylprednisolone showed lower recovery in
larger systems, although not significantly so. For propofol,
however, there was greater recovery in larger systems. The dif-
ferences are smaller than would be expected if system size
were the only factor involved.
Different components of the CPB system are capable of
absorbing drugs to their plastics. Differences in drug recovery
between different types of oxygenator have been described
extensively.5,16 With the new polymethylpentene and PLP
membranes the oxygenator does not appear to be a factor of
considerable interest in drug recovery anymore. Based on a
study by Preston et al., 80% of drug is lost to PVC tubing, with
a small additional amount of drug (of just 5%) lost to the oxy-
genator.17 Silicone tubing has been shown to decrease the
recovery of drugs compared with PVC tubing.2,8 The effect of
different surface coatings on both oxygenator and tubing on
drug recovery has been investigated by several authors,7,12,13
and those studies suggest different effects for different coat-
ings for different types of drugs. The addition of an arterial fil-
ter also may lead to decreased drug recovery.13 Many factors
thus are at play and interact with each other.
It is unclear which differences in system composition play a
role in the present study. The interplay of differences in sur-
face area, coating, tubing type, and pump type makes it diffi-
cult to draw firm conclusions about the influence of individual
system components on drug recovery. In an earlier study by
Preston et al., a Terumo Baby Rx oxygenator was used17. The
Terumo Capiox Fx05 was used in the present study’s neonatal
systems, which is the same oxygenator with the same mem-
brane, the same coating, and the same surface area, but with an
integrated arterial filter. The Baby Rx oxygenator absorbed
3% of fentanyl added to the system in the study by Preston
et al., which amounts to 0.6 ng/cm2. Raffaeli et al. showed that
sufentanil absorption is similar to fentanyl absorption in their
ECMO systems.9 Assuming the aforementioned holds true, the
amount of drug absorbed in the present study’s neonatal sys-
tems just by the tubing and the arterial filter would be 4.2 mg
of sufentanil at 180 minutes (total uptake of sufentanil 72% at
180 min of 10 mg added to the neonatal systems minus theamount absorbed by the oxygenator). Because the neonatal
systems in the present study had silicone tubing, this relatively
low amount of absorption seems unlikely.
A similar calculation for the pediatric systems used in the
present study is possible. The Capiox Fx15 oxygenator would
absorb 9 mg in total because of its larger surface area. After
180 minutes, 76% of the 60 mg of sufentanil added to the sys-
tem would be absorbed. Further calculation shows that this
would mean that the Sorin tubing would absorb 25.1 ng/cm2 of
sufentanil. This, however, would mean that all the sufentanil
in the neonatal system in the present study would have to have
been absorbed, which is not the case. For a more extensive cal-
culation, the reader is referred to the supplemental materials.
Hynynen et al.18 described propofol recovery of 25% after
120 minutes of circulation in an adult system. Hammaren
et al.12 and Myers et al.13 described recovery of 37% and 43%,
respectively, after 60 minutes. These values are remarkably
similar to those of the present study, even though completely
different CPB systems were used. Based on the calculations
previously described and the results by Hynynen, Hammaren,
and Meyers, it appears that it is very difficult to translate
research performed in individual centers to one’s own clinical
practice because of the amount of factors and interactions at
play. It is clear that not all factors influencing absorption to dif-
ferent components of CPB systems are known. A possible lack
of generalizability thus may be seen as a limitation to the pres-
ent study and other studies already performed in this field.
Several authors have found no influence of temperature
management on the recovery of drugs in their systems.16,19,20
Therefore the authors of the present study did not attempt to
simulate a cooling protocol.
Despite the significant decrease in recovery of drug from the
priming fluid of the CPB system found in the authors’ in vitro
studies, clinically patients do not wake up on initiation or dur-
ing CPB. A clinical study of propofol infusions in cardiac sur-
gery in adult patients showed no change or even a decrease in
bispectral index values during CPB.21 This most likely was
caused by an increase in unbound drug concentration as a
result of decreased protein concentration on initiation of
CPB,21-23 causing a greater amount of drug available for end-
organ effect.
The present study has several other limitations. Only com-
plete systems were tested, thus there is no information in the
present study as to which amount of drug was absorbed by
which system component. Unfortunately this type of research is
expensive because of the costs of systems, blood products for
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poses of the present study, namely the integration of these in
vitro results with the results of the in vivo part of the CPB
PHARM study, the authors sought to mimic everyday practice
in their hospital as closely as possible, making testing of indi-
vidual components less useful. For the same reasons, the authors
have not performed isolated drug studies. It is not known
whether there is competition for binding sites to components of
the CPB system for different individual drugs. Although theo-
retically this is an interesting topic, in clinical practice, patients
receive multiple medications at the same time.
Just 3 full systems in each category were used, and although
this may seem like a small number, the sample size is compa-
rable with that of other publications performed with both CPB
and ECMO systems and which are cited in this article.
Spontaneous degradation may have produced bias in the pres-
ent study because it causes a decrease in drug concentrations not
caused by adherence of drug to components of the CPB system.
Previous studies in the authors’ hospital have shown that sponta-
neous degradation over 24 hours for midazolam is 11.4% and
for sufentanil is 0%.9 For propofol, spontaneous degradation in
glass bottles with daylight and room temperature is around 5%
after 6 hours.24 For methylprednisolone, no references were
found for spontaneous degradation. Because degradation usu-
ally is calculated over 24 hours, the effect on the present study’s
results would be constant over time.
For the calculation of MEC, the authors did not correct for
blood-plasma ratio. In previous studies in the authors’ hospital,
midazolam was shown to have a blood-plasma ratio of 75%.8
Because the present study’s MEC value was calculated in
blood, but drug concentrations were measured in plasma,
MEC would be underestimated for midazolam. Because pro-
pofol is highly bound to red blood cells in vivo, a high blood-
plasma ratio would be expected and the present study’s MEC
would be overestimated.
The authors did not aim for a similar drug concentration in
the different types of CPB systems. Instead, the dose of drug
that would be administered to a typical patient connected to
a neonatal, infant, or pediatric CPB system in the authors’
daily clinical setting was added because the goal of the pres-
ent study was to mimic the authors’ everyday practice as
closely as possible so that in the future the authors will be
able to incorporate CPB system recoveries in a larger popu-
lation pharmacokinetic model of the influence of CPB on
drug concentrations in children.
Because of the high doses of drug added to the authors’ sys-
tems, drug concentrations were more than the ULOQ for some
drug assays, necessitating additional dilution before quantifica-
tion. The high doses also might have resulted in potential dif-
ferences in absorption rates, as has been shown for propofol.12
In the present study, indications that mixing of drug with the
priming fluid is not always complete were observed. This may
have clinical consequences if drugs are added to the CPB sys-
tem during CPB, rather than given directly to the patient.
Despite these limitations, to the authors’ knowledge, the
present study is the first comprehensive in vitro testing of CPB
systems used in pediatric congenital cardiac surgery.In conclusion, the present study’s in vitro experiment with
neonatal, infant, and pediatric CPB systems shows a variable
recovery of routinely used drugs with significant differences
among drugs but not among system categories, except for pro-
pofol. The study also demonstrates that the generalizability of
this type of research may be limited. The clinical consequen-
ces of the present study’s research must be investigated fur-
ther. The decreased recovery of sufentanil and propofol could
lead to suboptimal dosing of patients during cardiac surgery
with the use of CPB, even though clinically this doesn’t show;
thus it is important that these findings are integrated with the
results of in vivo studies into population pharmacokinetic
models to further investigate the clinical relevance of the pres-
ent study’s findings and the implications for perioperative
patient care.
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